SMN1 rAAV Vector Design for Lower SMA Gene Therapy Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal muscular atrophy (SMA), such as antisense oligonucleotides and gene replacement therapies, face challenges with toxicity and off-target tissue expression, limiting their effectiveness and safety.
Innovation Solution
Development of recombinant adeno-associated virus (rAAV) vectors with a codon-optimized nucleic acid sequence encoding SMN1, driven by a native SMN1 promoter, and incorporating miR-122 binding sites to reduce toxicity and improve transgene expression, using AAV2 or mutant ITRs for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional gene replacement therapies using AAV vectors are used to treat SMA, then SMN1 protein expression is increased, but toxicity in dorsal root ganglion and liver tissues occurs
Solution Approach 1:
The patent applies local quality by making the promoter region tissue-specific. The modified SMN1 promoter contains tissue-specific regulatory elements that restrict SMN1 expression to motor neurons while preventing expression in dorsal root ganglion and liver tissues. This spatial differentiation of gene expression resolves the contradiction by localizing the beneficial effect to target tissues while eliminating harmful effects in non-target tissues.
Solution Approach 2:
The patent modifies the promoter sequence parameters of the SMN1 gene to create a tissue-specific expression pattern. By changing the regulatory sequence parameters (adding tissue-specific elements, modifying transcription factor binding sites), the expression profile is altered from ubiquitous to motor neuron-specific, thereby resolving the toxicity issue while maintaining therapeutic SMN1 production in target cells.
2Productivity
If constitutive promoters are used to drive SMN1 expression in rAAV vectors, then transgene expression is enhanced, but off-target tissue expression causes toxicity
Solution Approach 1:
The invention replaces constitutive promoters with modified tissue-specific promoters that confer motor neuron specificity. This creates localized gene expression restricted to the desired tissue type, eliminating off-target expression in liver and dorsal root ganglion while maintaining high expression levels in motor neurons through optimized promoter strength and regulatory element selection.
Solution Approach 2:
The patent converts the potential harm of strong promoter activity (which causes off-target expression and toxicity) into a benefit by using tissue-specific regulatory elements. The same promoter strength that drives high expression is now selectively activated only in motor neurons through tissue-specific transcription factor binding sites, transforming the harmful ubiquitous expression into beneficial localized expression.
Data Source
AI summary
Aspects of the disclosure relate to compositions and methods for treating spinal muscular atrophy (SMA). The disclosure is based, in part, on isolated nucleic acids and vectors (e.g., viral vectors, such as rAAV vectors) encoding SMN1. In some embodiments, the expression of SMN1 is driven by a native SMN1 promoter or a variant thereof. In some embodiments, isolated nucleic acids and vectors of the disclosure have reduced toxicity and/or increased transgene expression relative to previously described SMN-encoding vectors.